European OTC Switch Still Muted By Regulatory Resistance
This article was originally published in The Tan Sheet
Executive Summary
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.
You may also be interested in...
U.K. Regulator To “Streamline” Switch Approach With Guidance
U.K.’s health authority issued guidance that industry representatives say will help cut months off the time to reclassify a prescription drug to nonprescription, Pharmacy sale. OTC trade group emphasizes the guideline calls for more engagement before firms submit applications.
U.K. Regulator To “Streamline” Switch Approach With Guidance
U.K.’s health authority issued guidance that industry representatives say will help cut months off the time to reclassify a prescription drug to nonprescription, Pharmacy sale. OTC trade group emphasizes the guideline calls for more engagement before firms submit applications.
U.K. Regulator To “Streamline” Switch Approach With Guidance
U.K.’s health authority issued guidance that industry representatives say will help cut months off the time to reclassify a prescription drug to nonprescription, Pharmacy sale. OTC trade group emphasizes the guideline calls for more engagement before firms submit applications.